Trade

with

ZIOPHARM Oncology Inc
(NASDAQ: ZIOP)
AdChoices
2.55
+0.08
+3.24%
After Hours :
2.55
0.00
0.00%

Open

2.49

Previous Close

2.47

Volume (Avg)

1.45M (700.21k)

Day's Range

2.44-2.59

52Wk Range

2.31-5.58

Market Cap.

248.83M

Dividend Rate ( Yield )

-

Beta

1.99

Shares Outstanding

100.74M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 800.00k

    • Net Income

    • -57.11M

    • Market Cap.

    • 248.83M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -5,112.88

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.99

    • Forward P/E

    • -

    • Price/Sales

    • 294.12

    • Price/Book Value

    • 6.60

    • Price/Cash flow

    • -5.63

      • EBITDA

      • -56.98M

      • Return on Capital %

      • -81.04

      • Return on Equity %

      • -143.40

      • Return on Assets %

      • -81.04

      • Book Value/Share

      • 0.37

      • Shares Outstanding

      • 100.74M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -5,112.88

            • 39.38

            • Net Profit Margin

            • -5,112.88

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.01

              • 2.92

              • Quick Ratio

              • 4.92

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.47

              • 2.21

              • Book Value/Share

              • 0.37

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -5.62

                • 238.10

                • P/E Ratio 5-Year High

                • -18.15

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.45

                • 124.82

                • Price/Sales Ratio

                • 285.71

                • 8.94

                • Price/Book Value

                • 6.49

                • 8.12

                • Price/Cash Flow Ratio

                • -5.63

                • 47.85

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -143.40

                        (-111.40)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -81.04

                        (-66.50)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -143.40

                        (-111.40)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.02

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -57.71M
                      Operating Margin
                      -7,214.13
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -5.63
                      Ownership

                      Institutional Ownership

                      63.06%

                      Top 10 Institutions

                      55.58%

                      Mutual Fund Ownership

                      14.82%

                      Float

                      80.59%

                      5% / Insider Ownership

                      2.70%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • SPDR® S&P Biotech ETF

                      •  

                        2,025,786

                      • 0.60

                      • 1.92

                      • Fidelity® Select Health Care Portfolio

                      •  

                        2,000,000

                      • 0.00

                      • 1.99

                      • Prudential Jennison Health Sciences

                      •  

                        1,501,767

                      • 0.00

                      • 1.49

                      • Vanguard Total Stock Mkt Idx

                      •  

                        1,329,839

                      • 0.00

                      • 1.32

                      • iShares Russell 2000 (AU)

                      •  

                        1,264,309

                      • -1.00

                      • 1.20

                      • Vanguard Extended Market Index Fund

                      •  

                        1,038,663

                      • 0.47

                      • 1.03

                      • iShares Russell 2000 Growth

                      •  

                        607,798

                      • 0.77

                      • 0.58

                      • Fidelity Advisor® Health Care Fund

                      •  

                        404,100

                      • 0.00

                      • 0.40

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        334,171

                      • 0.00

                      • 0.33

                      • CREF Stock

                      •  

                        258,687

                      • 3.70

                      • 0.26

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Third Security, LLC

                      •  

                        17,815,708

                      • 0.00%

                      • 17.69

                      • Fidelity Management and Research Company

                      •  

                        4,413,607

                      • -40.82%

                      • 4.38

                      • State Street Corp

                      •  

                        3,753,085

                      • -10.80%

                      • 3.73

                      • Vanguard Group, Inc.

                      •  

                        2,855,937

                      • +12.49%

                      • 2.84

                      • Essex Woodlands Health Ventures

                      •  

                        2,764,908

                      • 0.00%

                      • 2.75

                      • MSDC Management, L.P.

                      •  

                        2,750,000

                      • 0.00%

                      • 2.73

                      • BlackRock Fund Advisors

                      •  

                        2,032,142

                      • -9.75%

                      • 2.02

                      • Belmont Global Advisors, Inc.

                      •  

                        1,785,522

                      • -21.34%

                      • 1.77

                      • Jennison Associates LLC

                      •  

                        1,515,784

                      • -10.19%

                      • 1.50

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Core

                      ZIOPHARM Oncology, Inc. is a Delaware Corporation originally incorporated in Colorado in September 1998 under the name Net Escapes, Inc. and later changed its name to "EasyWeb, Inc." in February 1999. Following reincorporation in Del...moreaware in May 2005 under the same name, the Company completed a reverse acquisition of privately held ZIOPHARM, Inc., a Delaware corporation on September 13, 2005. It is a biopharmaceutical company that seeks to acquire, develop and commercialize, on its own or with commercial partners, a portfolio of cancer therapies through synthetic biology. Palifosfamide, ZIO-201 is a small molecule palifosfamide, or isophosphoramide mustard, is a proprietary active metabolite of the pro-drug ifosfamide. Small-Cell Lung Cancer, or SCLC, is almost exclusively associated with smoking. S...moretandard of care for SCLC, which is etoposide and platinum therapy, has changed little in decades. Darinaparsin, ZIO-101. Darinaparsin is an anti-mitochondrial compound covered by issued patents and pending patent applications in the United States and in foreign countries. Indibulin, ZIO-301. Indibulin is a novel, small molecule inhibitor of tubulin polymerization and is potentially safer than other tubulin inhibitors as no neurotoxicity has been observed in preclinical studies or in Phase 1 clinical trials. The Company is subject to government regulations.lessless

                      Key People

                      Dr. Jonathan Lewis,M.D.,PhD

                      CEO/Director

                      Dr. Murray Brennan,M.D.

                      Chairman of the Board/Director

                      Kevin G. Lafond

                      CFO/Chief Accounting Officer/Treasurer/Vice President, Divisional

                      Mr. Caesar J. Belbel

                      Executive VP/Other Executive Officer/Secretary

                      Randal J. Kirk

                      Director

                      • ZIOPHARM Oncology Inc

                      • One First Avenue, Parris Building 34

                      • Boston, MA 02129

                      • USA.Map

                      • Phone: +1 617 259-1970

                      • Fax: +1 617 241-2855

                      • ziopharm.com

                      Incorporated

                      1998

                      Employees

                      43

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: